“The alternative is they’re not getting care at all”: a qualitative interview study of opioid use disorder treatment providers’ perspectives on quality and appropriateness of telehealth for buprenorphine access Authors: Naomi Zucker, Emilio Flores, David Mandell, Justin Clapp, Shoshana V Aronowitz Published: 2026 ABSTRACT AbstractBackgroundOpioid use disorder (OUD) is a major source of morbidity and mortality in the United States. While substantial evidence supports the effectiveness of medications for opioid disorder (MOUD), 80% of people with OUD receive no treatment, and of those who do, less than half receive MOUD. Since the Covid-19 pandemic, there has been a substantial increase in the use of telehealth to deliver MOUD care. While telehealth has shown promise for increasing access and improving retention in treatment, its ongoing uptake and provision will depend on its acceptance and implementation by providers. This qualitative, interview-based study aims to explore how providers understand, experience, and assess telehealth for MOUD in the wake of its rapid expansion.MethodsWe conducted 25 in-depth, semi-structured interviews with MOUD providers in Southeastern Pennsylvania, including prescribing clinicians, clinic staff, mental health counselors, program administrators/leadership and pharmacists. We recruited from diverse substance use disorder treatment settings, using purposive and snowball sampling. Interviews were conducted over Zoom, transcribed, and coded and analyzed using iterative thematic coding.ResultsWhile most providers hold largely positive views of telehealth for MOUD due to its ability to improve access, they differed in their assessments of how such care compares to in-person MOUD treatment and for whom it is most appropriate and effective. Our findings show that debates over telehealth center on perceived quality of care and the “stability” of patients. Despite these disagreements, providers largely agree that telehealth is “better than nothing.”ConclusionsWhile most providers hold largely positive views of telehealth for MOUD, hesitation towards telehealth is linked to assumptions about the broader empirical state of in-person MOUD treatment and about patient needs, preferences, and capacities to engage in care. Understanding when and why providers may oppose the use of telehealth for MOUD is critical to improving care for patients and reducing barriers to a form of treatment that can increase access to much-needed care for the most vulnerable patients.Keywords: Opioid use disorder, Medications for opioid use disorder, Buprenorphine, Telehealth, Stigma Background Even as opioid overdose and death have reached record heights in the United States, constituting a major cause of morbidity and mortality, treatment for opioid use disorder (OUD) remains inaccessible to many people who could benefit from it [1]. While substantial evidence supports the use of medications for opioid use disorder (MOUD), more than 80% of people with OUD receive no treatment, and of those who do receive care, less than half receive MOUD [2]. Barriers to care are well documented, and include geographic distance; transportation challenges; work, childcare and other caregiving obligations; stigma against both people who use drugs and MOUD as a treatment; and too few providers offering MOUD care [1–3]. At the onset of the Covid-19 pandemic, some OUD care moved online; the initial demands of social distancing and subsequent loosening of regulatory restrictions made telehealth a useful and viable option for delivering some treatment options safely [4, 5]. Since 2008, The Ryan Haight Online Pharmacy Consumer Protection Act had required initial prescriptions of controlled substances, including buprenorphine, to be made in person. However, these requirements were lifted in March 2020 [6]. This regulatory change was initially envisioned as temporary but has been repeatedly extended, with the fourth and most recent temporary extension announced through December 31, 2026 [7], marking an important shift in the landscape of options for providing buprenorphine [8]. While methadone prescribing for OUD remains more tightly controlled and can only be administered at a certified Opioid Treatment Program (OTP), buprenorphine care can now be provided fully remotely by any prescriber with a Drug Enforcement Agency (DEA) registration. As a result, more patients and providers have gained experience with telehealth for buprenorphine prescribing (tele-bupe), which, while still a relatively new approach, has increased widely in use [9]. We use the term “tele-bupe” to capture a range of formats for remote provision of buprenorphine for OUD treatment. This includes full telehealth, where both patient and provider are remote, but may also include arrangements where patients are remote but providers are in the clinic, or vice versa. This care may also include the remote provision of other supportive services that can accompany medication provision, such as therapy and case management. While for some patients receiving tele-bupe, their full treatment will take place remotely, in other cases, telehealth may be used in concert with in-person care. For example, some clinics may offer some percentage of appointments remotely but require periodic in-person appointments, and some may require patients to come in person for physical assessments or urine drug screens. As tele-bupe has become more common, an emergent literature has mapped the possibilities and limitations of this modality of care. This growing body of evidence suggests that tele-bupe is as effective as in-person care [10–13], and that telehealth matches or exceeds patient retention in care compared with in-person treatment [8, 14–18]. There is a growing consensus that telehealth improves treatment access by overcoming important barriers to care like distance, transportation, time, and stigma [19–21]. Main barriers and points of concern include problems with technology, concerns over toxicology and regulatory compliance, loss of access to other in-person medical and social services, and perceived effects on clinician-patient relationships [19, 20]. While patients and providers alike hold generally positive opinions about tele-bupe, some providers remain more hesitant about this modality of care [20]. An important open question is for which patients tele-bupe is an “appropriate” treatment option, and how clinician-perceived patient “stability” can impact when and to whom this flexible treatment option is offered [22]. Following the rapid expansion of telehealth for OUD care during and since the Covid-19 pandemic [23], an upsurge in research has sought to understand the implications of this modality of care for patient outcomes and clinical practice [24–28]. One central consideration has been quality of care, with an emphasis on clinician-patient relationships and rapport-building [20, 29–31]. As historians of medicine have shown, anxieties about mediation often haunt the introduction of new technologies in medical practice [32–34], and questions about the nature and quality of clinical relationships in telehealth have remained contested, with some research describing improved relationships and others expressing skepticism about building rapport remotely. Such mixed views are documented in the emergent literature on tele-bupe; while patients and providers alike have overall positive opinions of telehealth, providers are generally more likely than patients to remain skeptical of its relational downsides [20]. The effectiveness of low-barrier and flexible OUD treatment has been well-documented [35–38]. However, both condition stigma for people who use drugs and intervention stigma towards particular forms of treatment for opioid use disorder remain common [39–43]. While barriers to OUD treatment continue to prevent patients from accessing lifesaving treatment [44–46], low-barrier treatment approaches to care are still not widely taken up in public health policy, nor always accepted by providers [47–49]. In this qualitative interview-based study, we explored how providers understand and experience tele-bupe in the wake of its rapid expansion. As tele-bupe has become more broadly accepted in OUD treatment environments, disparities in which patients have access to flexible treatment options remain. These disparities threaten to create a tiered system in which some patient populations can receive care in a way that is amenable to their schedules, private, and accommodating (via telehealth), while others must comply with treatment requirements that are more rigid and inflexible. This possibility mirrors the tiered system of care that emerged when buprenorphine first became available, and was only offered to specific patients deemed not appropriate for methadone (mostly white, wealthy, suburban individuals) [50]. We aimed to assess how providers make decisions about when and to whom to offer OUD treatment via telehealth, with the goal of understanding clinician decision-making around this issue, which has not been sufficiently described in the literature. Results from this study can inform clinician training and interventions to better prepare clinics to offer tele-bupe to a diverse range of patients. Methods We conducted 25 in-depth, semi-structured interviews with OUD treatment providers in Southeastern Pennsylvania. To capture a full range of experiences and perspectives, we defined “providers” broadly as people involved in organizing and delivering OUD care to patients, including buprenorphine-prescribing clinicians (physicians, nurse practitioners, physician assistants), clinic staff, mental health counselors, program administrators/leadership and pharmacists. While not all participants directly prescribed medications, all had exposure to telehealth in the organizations in which they worked and were directly involved in patient care. We recruited from diverse OUD treatment settings, including community health organizations, harm reduction programs, major university medical systems, and Federally Qualified Health Centers. Participants were based in Southeastern Pennsylvania, including Philadelphia and, while most served patients in the Philadelphia area, some may have been providing treatment to patients in different geographic locations across the state. The study team began recruitment using purposive sampling, reaching out to potential participants and OUD treatment settings known to the team and sharing an IRB approved graphic describing the study. We then used snowball sampling, asking participants to refer others who met inclusion criteria. Given the diversity of our sample in terms of relevant participant roles and their extensive, highly relevant experience working with OUD patients in various capacities, our previous qualitative work in this area, and the exploratory aim of our study (to understand a range of provider perspectives on tele-bupe as it becomes more regularly integrated into present practice), we determined that 25 interviews achieved an appropriate level of information power [51]. Interviews were conducted remotely over Zoom between December 2023 and May 2024. Interviews were conducted by the PI, an assistant professor of nursing and nurse practitioner with extensive experience in OUD treatment and harm reduction service provision, and a research assistant with a bachelor’s degree and experience working as a case manager for people with substance use disorders. Interviews followed a semi-structured interview guide consisting of nine core questions about providers’ general experiences providing OUD treatment and specific experiences with (and opinions about) tele-bupe as a modality of treatment. Interviews asked about providers’ roles in their clinics, their current telehealth practices, their opinions about tele-bupe, and how they believed their clinics might better serve their patients (e.g. “What are your thoughts about telehealth for opioid use disorder treatment? For which patients is telehealth an effective treatment option? How do you think clinics might improve patient retention and patient experiences in care?”). In particular, interviews aimed to capture how telehealth is currently being used in MOUD care in their practices, and to probe when and for whom providers thought telehealth was most appropriate, desirable, or effective. Data collection was inductive in orientation; while we used a predetermined semi-structured interview guide, questions were broad and open-ended, allowing for the core focus of the subsequent analyses to be guided by participant responses. Data analysis began concurrently with the interview phase of the study, and findings and insights from early interviews were used to refine the interview guide and inform ongoing analysis. All interviews were recorded, professionally transcribed, and de-identified for analysis. Participants received $50 gift cards as compensation for their participation in the study. All study protocols were reviewed and approved by the University of Pennsylvania Institutional Review Board (IRB). Data analysis was conducted by three members of the research team: the two interviewers described above, and a postdoctoral fellow with a PhD in medical anthropology and experience interviewing patients and medical professionals about experiences with medical care and drugs. Throughout data collection and analysis, our research team explicitly sought to maintain a non-judgmental, non-stigmatizing orientation towards drug use and its treatment, and to remain attentive to the ways in which various providers roles and positions (as well as our own) may influence understandings, perceptions, and analyses of tele-bupe. Transcripts were imported into Dedoose, and the study team took an inductive approach to coding and data analysis based on iterative thematic coding [52, 53]. As a first step in analysis all team members familiarized themselves with the full data set by closely reading transcripts, annotating and note taking, and meeting together to discuss patterns, insights, and contradictions. Two members of the research team open coded a selection of interviews, which were used for initial code generation and to develop a preliminary codebook. This codebook was then used to code all remaining interviews, which were independently coded by two members of the team. The research team met regularly during the coding process to refine the codebook, discuss key themes and preliminary insights, and resolve any discrepancies. Disagreements were resolved through discussion and consensus, with a third researcher serving as an arbitrator when necessary. After full coding of the dataset, the team reached consensus on core analytical themes, and a second round of coding was conducted using the finalized codebook, which was updated to reflect themes of interest in greater detail. Findings We interviewed 25 participants, aged 24–73, who are involved in the provision of OUD care (we use the term “providers” to encompass all study participants) in Southeastern Pennsylvania. Participants included twelve prescribing clinicians (physicians, nurse practitioners, and physician assistants), seven members of clinic leadership, seven clinic staff (e.g.: care managers, program coordinators), two pharmacists and two mental health counselors. Some participants held multiple roles, for example, a medical director (clinic leadership) who is also a prescribing clinician. See Table 1 for more information about participant demographics. Table 1Participant demographics and rolesIDAgeRace + ethnicityGenderSelf-described professional roleRole (Categorized)144White, non-HispanicWomanProgram managerClinic leadership251Bi-racialWomanNurse practitionerPrescribing clinician336White, non-HispanicMan/non-binaryPhysicianPrescribing clinician451White, non-HispanicManPhysician, Medical directorPrescribing clinician/clinic leadership554White, non-HispanicWomanPhysician, Medical directorPrescribing clinician/clinic leadership630White, non-HispanicNon-binaryCare managerClinic staff733White, non-HispanicNon-binaryPsychotherapistMental health counselor848White, non-HispanicManPhysician, Medical directorPrescribing clinician/clinic leadership936White, non-HispanicWomanClinical directorClinic leadership1033White non-HispanicTrans non-binaryProgram coordinatorClinic staff1127WhiteTrans-masculineHealth care navigatorClinic staff1241WhiteWomanCommunity outreach coordinatorClinic leadership/pharmacist1373WhiteManPhysicianPrescribing clinician1424WhiteWomanPatient care pharmacistPharmacist1546WhiteWomanPhysician AssistantPrescribing clinician1632Black, non-HispanicWomanProject managerClinic staff1757WhiteManPhysicianPrescribing clinician1826White, non-HispanicNon-binaryProject managerClinic staff1930White, non-HispanicManPsychotherapistMental health counselor2045White, non-HispanicWomanIntake liasonClinic staff2139White, non-HispanicWomanMedical directorPrescribing clinician/clinic leadership2240Black, non-HispanicWomanMedical assistantClinic staff2334White, non-hispanicWomanNurse practitionerPrescribing clinician2438White, non-HispanicWomanNurse practitionerPrescribing clinician2540Black, non-HispanicWomanNurse practitionerPrescribing clinician Participant demographics and roles Overall, participants held generally positive views about tele-bupe. While enthusiasm for telehealth as a modality of treatment varied across participants, almost all acknowledged that it was helpful and appropriate in certain contexts. Most participants gave measured, considered assessments of telehealth that acknowledged both its strengths and weaknesses, often moving back and forth between them in the same response. Participants widely acknowledged that telehealth is more convenient for and accessible to patients, making it a good option in cases where treatment might otherwise be overly difficult to access; in particular, they noted the utility of telehealth for patients in rural or poorly served areas; patients who are disabled, sick, or injured; and patients with caregiving or work responsibilities that make in-person appointments difficult. Despite this broad agreement that telehealth can improve access, participants differed in their assessments of how such care compares to in-person OUD treatment and for whom it is most appropriate and effective. In what follows, we focus on these two broad areas of heterogeneity, exploring differences in participant opinion over (1) quality of care and (2) appropriate patients for tele-bupe. We then describe how, despite these disagreements, providers largely agree that telehealth is (3) “better than nothing.” Quality of Care. Quality of Care. Quality of care was a major feature of providers’ deliberations over tele-bupe. Providers in our study varied significantly in how they understood the relationship between telehealth as a modality and the quality of care delivered to patients: some believed telehealth led to a lower quality of care, others that in-person care and telehealth were largely equivalent, and others that telehealth allowed for superior quality of care. 1.1 “There’s Just Something That you Get from Seeing Someone in Person”: Telehealth as Lower Quality of Care. “There’s Just Something That you Get from Seeing Someone in Person”: Telehealth as Lower Quality of Care. Some participants articulated a sense that telehealth is fundamentally worse than in-person treatment. Participant 6, a care manager, expressed this understanding: So my actual honest opinion about telehealth is that it is bad. I just do not think it’s as effective as being in the same room as someone…Actually physically being with someone in a room is a higher level of human connection. And that reflects on the quality of the therapy, reflects on the quality of the care management. I do the same work, whether it’s telehealth or in person, but what the patient receives is of a lower…they’re receiving a lower volume of quality care. For the providers we interviewed, the idea that telehealth is in some essential (if sometimes unspecified) way a compromise in quality of care was based in large part on how it affects provider-patient relationships and modes of interaction between them. Providers articulated their dissatisfaction with telehealth in relation to building trust and rapport; having insight into patients’ lives and conditions; and the benefits to patients of the “structure” of having to show up for an in-person appointment. Rapport The idea that some critical “human” quality is lost in remote care was expressed by a number of providers, who thought that face-to-face connection was important to building relationships with patients. Participant 24, a nurse practitioner, was generally supportive of tele-bupe and believed good outcomes were possible in this modality. Yet, she still qualified her support, emphasizing that for relationship-building, in-person care was superior: I do think there is something that’s nice, particularly when you’re building a relationship with somebody, to have like a face-to-face piece of it too. I’m trying not to say that I’m anti-telehealth because I’m not, but I do believe that human connection and face-to-face connection can be a powerful thing. Participant 13, a pediatrician who treats addiction in adolescents, was strongly opposed to telehealth for the patients he works with, because he views the kinds of relationships he wants to build with them as requiring the intimacy of the in-person encounter. I form a relationship with the patients. I mean, more than just on the phone. We talk, we joke around – I educate them. And we talk about various things. And so, just the comfort of being in an actual office, talking to somebody, it’s – I don’t write a script and throw them out. We talk when they come and see how they’re doing and address various issues. In this account, in-person care indexes a more robust, organic, and comprehensive mode of engagement than telehealth, one in which provider and patient can have a more casual, closer relationship, supported by the “comfort” of the office environment. Rapport is thus a core domain which captures providers’ overall feelings about the gestalt of tele-bupe, and their sense that something is lost in the translation from in-person to virtual treatment. Insight If some providers believed that in-person treatment was more conducive to building rapport and to forging a stronger therapeutic alliance, others felt that it also offered greater insight into patients’ physical and mental states. Telehealth, from this perspective, makes it harder to accurately assess patients, thus potentially compromising their care. In the words of participant 22, a medical assistant: I just think that having a practitioner actually see that person and be in the room with that person…They can get a better feel for where they’re at and how they’re feeling. Providers expressed concern that without in-person contact, they might not be able to catch when their patients are struggling: “I worry that you might miss things, that it might take longer to catch on to the fact that someone’s not doing very well, or that they’re struggling, when there’s not really—‘Ann looks good today, Ann doesn’t really look good today’—without the in-person touch.” (Participant 10, program coordinator). Participant 25, a nurse practitioner, suggested that it might not only be harder for providers to assess what was going on with their patients without in-person presence, but also that telehealth might enable patients to lie to their providers: I think that there is just something about seeing people in person to get a better idea of where they are in their recovery process that is just hard to get over the phone…there’s just something that you get from seeing someone in person…There are plenty of times where I’ve talked to people on the phone and they sound fine. They’re like, oh yeah, I’ve been taking my [buprenorphine], I’m not really using that much…And then they come in and you’re like, this does not line up with what you’re telling me…You’re telling me that you’re taking your [buprenorphine], but it does not line up with what I’m seeing in front of me… So I do think that it’s missed. Alongside and entwined with concerns over patient well-being are hints of the desire for surveillance, where telehealth is perceived as a less-accurate window into patients’ use of drugs and an opportunity for dishonesty to go undetected. Participant 19, a mental health counselor, voiced similar concerns, framing telehealth as a site of possible deception: So I think that there’s more that the provider can maybe see and feel in person when the person is in the room. There’s less of an ability to sort of hide something or pretend or whatever, as one can maybe virtually for the five minutes that they’re there. When a person comes to the clinic, they’re there for a much longer amount of time. So likely, they won’t be able to continuously act in a certain way to get over on someone or to trick someone or whatever. Beyond the specific relational benefits of the in-person clinical interaction, these providers identified an informational benefit that they believed improved the quality of care. Structure Finally, some providers felt an added benefit of in-person care was precisely the fact that it required people to make the effort to have to show up in person. While this effort has often been seen as a barrier to care—with telehealth offering easier and more flexible access—for some providers, the effort is part of what makes care worthwhile and effective: Participant 19, a mental health counselor, emphasized the importance of the structure in-person visits impose, especially in the sometimes-chaotic lives of their patients: Behaviorally, I think it’s good for a person to have to be somewhere at a certain time. And it provides some structure into a life which many live without. For Participant 20, an intake liaison, putting in “the work” is an important part of recovery, and committing to in-person treatment requires more effort on the part of patients than telehealth: I don’t think [telehealth] works. I’m kind of a middle harm reductionist, but I believe that sobriety – recovery, let’s not even say sobriety – recovery, it takes a lot of work. It takes a lot of continued work…it’s a lot of work to live every day with substance use disorder and the things that you have to do…So, I think that, conversely, we need to put as much work into our recovery. This idea that recovery does (and should) take work and effort inverts what is often seen as a drawback of in-person care into something that certain providers feel supports recovery. In this way, providers discuss a kind of structural benefit to in-person treatment, which they believe makes demands of patients that are good for their treatment and make care more effective. These relational, informational, and structural features led some providers to view in-person care as superior to telehealth. 1.2“What Does the Provider Do In-Person, Really?”: Telehealth as Equivalent to In-Person Care. “What Does the Provider Do In-Person, Really?”: Telehealth as Equivalent to In-Person Care. While some participants were wary of telehealth’s impact on the quality of care they could deliver, others disagreed that one modality was inherently better than the other. For many participants, providing MOUD in-person was virtually indistinguishable from doing so over telehealth. Discussing tele-bupe, Participant 19, a mental health counselor, reflected: I mean, what does the provider do in-person, really? They read the top screens on the computer, and they speak with the person. So I think they could do all those things virtually as well. I don’t think it would limit…I think for Suboxone purposes, when it comes to just seeing if they have drugs in their system from last week’s drug test, and just asking the person questions about the symptoms that they’re feeling or whatever, I think that telehealth is fine. When asked if she felt quality of care differed between in-person and telehealth, Participant 23, a nurse practitioner, insisted it did not: Quality of care? No. It was interesting, they still had the case manager call the patient before I did, and they still did the same kind of check-in that they would do if the person was physically in building, which was really nice. If the nature and quality of care offered via telehealth was, for some, indistinguishable from that offered in person, some providers also believed that achieving strong clinical relationships was just as possible over telehealth as in person. While Participant 24, a nurse practitioner, had expressed some concern over the loss of face-to-face interaction in remote care, she also reflected on how “great relationships” could still be built over telehealth: I don’t think it’s necessarily impossible to do it for telehealth…I did a [telehealth] rotation during my nurse practitioner training. I definitely saw the folks who are practitioners there building great relationships with people. So I don’t think it’s impossible. I think things like people’s stability of their lives, being able to be in a quiet place, being able to have access to like good cell service, all those things affects the ability to have a successful call. And so, if all those things are in place, then I think like it’s kind of - it’s a good environment that’s been created for like a good conversation to have. And I think that you can build trust through telehealth modalities. In this case, if the right conditions are met, telehealth can create the “good environment” required for building trusting, robust clinical relationships. Participant 7, a mental health counselor who used telehealth to provide OUD-specific psychotherapy, admitted that despite a gut feeling that in-person care was better, in fact, rapport building was perfectly achievable over telehealth: I feel like I’m contradicting myself, because I feel like the rapport building, getting to know [someone], building trust, that can absolutely happen over the phone. I feel like what I’m doing right now in private practice proves that, like I’m doing hour-long therapy sessions over telehealth…I feel like there really is no difference in the kind of therapeutic relationship I build in-person versus telehealth. Participant 8, a physician and medical director, similarly saw no clear advantage to in-person care: Yeah, I don’t think there’s any difference from a therapeutic relationship standpoint unless the patient really needs that. I don’t need that. Quite the opposite. For some providers, quality of care was thus largely unaffected by the choice of in-person or remote treatment. 1.3“A Greater Chance to Keep People Engaged in Care”: Telehealth as Superior to In-person Care. “A Greater Chance to Keep People Engaged in Care”: Telehealth as Superior to In-person Care. For some, telehealth is not only as good as in-person care, but ultimately a better option for many patients. If there is no loss in the quality of care offered as compared to in-person, and patients are more likely to present to appointments, stay in touch, and fit ongoing treatment into their busy and ever-changing lives, they are more likely to build better, lasting therapeutic relationships and to stay engaged in treatment over the longer term. Participant 18, a project manager, explained: I mean, the data shows that, like, people…have, like, pretty equivalent outcomes, if not better, to connecting to care with our [buprenorphine] virtual bridge clinic, but also, people really do stay in touch. People still build relationships and still can really get…what they need, I think, in a really low-barrier way, especially for people who have mobility challenges, transportation challenges, maybe are on house arrest. Here, telehealth is both accessible to more people who may otherwise find their access to care limited, and a site of strong, ongoing relationships between services, providers, and patients. Participant 16, another project manager, agreed: If we’re thinking about the whole person in recovery, as people…get stable, they find employment, and they may decide to have children…you know, all lives are complex, so it definitely offers a layer of flexibility with people’s schedules, that I think most practices could benefit from. It’ll help to get people in the door, at least…you could still build rapport, and I do think that it is an effective way to reach people longitudinally. It may even offer a greater chance to keep people engaged in care, which is what we want, so. Participant 8, a physician and medical director, felt strongly that excellent care is possible via telehealth, which allows people to continue to receive high-quality, evidence-based treatment that might not be available in all locations: I mean, I have patients that I still treat even though they’ve moved far away and I don’t think they’ll get as good care if they establish with someone new. I don’t think they’ll get as good care outside of our county. I know how that may sound, but a lot of patients don’t get evidence-based treatment when they move away from here. So it’s allowed me to maintain a relationship with some of the most vulnerable patients that I treat. It’s been most helpful…I think those are the patients that we’ve kept in care. Not only does telehealth allow patients to access high-quality, evidence-based services that they may not otherwise have access to, it also protects patient and provider relationships over time: You establish a therapeutic relationship and you have that long-term through ups and downs. So that’s who I think it helps the most because it allows the patient to stay with one provider. Because I actually don’t think that there’s a cookbook for providing buprenorphine treatment. I actually think it’s very dependent on the therapeutic relationship. And people are gonna find what meets their needs. In this account, both structural and relational features make telehealth the best option for some patients: the ability to more easily, safely, and comfortably get to (and stay in) treatment is here understood as part of what it means to provide quality care. 2.0Who is Telehealth for? Who is Telehealth for? If participants in our study expressed disagreement over if and how telehealth affects quality of care, they also articulated conflicting views over the most appropriate patients for tele-bupe. In particular, when asked about which patients were best suited for treatment via telehealth, many participants invoked the notion of “stability.” Stability, while not always formally defined by providers, is the taken-for-granted criterion many use when reasoning about who is most likely to benefit from (or not be harmed by) foregoing in-person MOUD care in favor of telehealth. Assessments about patient stability involve (and sometimes conflate) a sense that patients are high-functioning, socio-economically stable, well-established in treatment, and unlikely to lie and/or divert their medications. While the majority of study participants believed that telehealth was most appropriate for stable patients, others felt that it was in fact of greatest benefit to the least stable, most vulnerable patients in need of care. 2.1Best for “Stable” Patients. Best for “Stable” Patients. Many providers saw the ideal subjects of telehealth MOUD as “stable” patients whose lives were sufficiently socially and economically secure and whose adherence to treatment had already been established. In contrast, they believed that less stable patients, whose life situations were more precarious and whose adherence they may have doubted, were less likely to benefit from this modality of care and required the more intensive supervision they associated with in-person treatment. For many providers, the stability required for telehealth involves having demonstrated treatment adherence over time and steady progress in recovery. Participant 3, a physician, noted: Generally speaking, we try to reserve telehealth MOUD for folks who are more stable. And stable generally means that they’ve demonstrated adherence a few times, they come to their visits on time or they call when they can’t make it and they’re meeting their own sort of recovery goals. Participant 10, a program coordinator, likewise framed telehealth as appropriate for a certain moment in one’s treatment trajectory, after one has achieved a level of stability: I think telehealth can be really great. I do think that it is a more advantageous tool after a certain threshold of sobriety or after a certain threshold of recovery, when a person is more stable…I don’t know how I feel about our own patient population, but I do definitely think it could be helpful for the right population that is doing well. The “right population” for telehealth, here, is one that is already deemed to be “doing well”; patients like those with whom this provider works at a low barrier clinic (many of whom who are unstably housed, unemployed, living with concurrent mental health issues, and/or using multiple substances) are considered insufficiently stable for this form of treatment. Participant 1, a program manager, gave a typical description of the patient population many providers associate with telehealth: There was this population that we didn’t really know existed, but does exist, meaning they’re in care for a long time. They have a telephone; they have a job, [they’re] really high functioning. And they are…high functioning technology-wise, meaning they’re really able to navigate a system and don’t need the wraparound services. I know people that have been on [buprenorphine] for ten years, why would they have to go in every week or do counseling because the program says so, or take off from work? While she thinks telehealth is a “fantastic” option for “anyone that wants it and can access it,” the ideal telehealth patient is here understood to be employed, technologically competent, and generally socially stable. Participant 12, an outreach coordinator, echoed this characterization of telehealth’s ideal patient: But I think, like, for professionals, people who are working full time, I think it’s great for those folks. In contrast to the stable, employed, professional-class patient, providers worried that telehealth may not be appropriate for those in situations of greater social vulnerability and precarity, who may lack health literacy and access to technology and may need more intensive social support than they believed telehealth could offer. Participant 25, a nurse practitioner, explained: I think it’s a great option for people who want a quick start, but I don’t necessarily think it’s a good long-term option…. In this underserved community, let me say that…People who are actively homeless…or are in underserved communities…who have limited health literacy. I don’t think that it’s best for those people. I think it’s harder for them to engage virtually…And I know a lot of my patients, they don’t keep a phone number for more than a year. A lot of times, a lot of them switch phones or the phone is off at some point in time, or they’re unhoused. So you’re catching them where they’re on the subway and the call drops, or you can’t hear them because the [subway train] is going by. So all of those things really break up the ability to connect with someone in a way where you’re really going to be able to focus in on the care. It just kind of becomes, like, ‘okay, all right, we’re here, I’m going to send your [buprenorphine] films. Okay, bye-bye.’ You know what I mean? This sense that telehealth cannot offer the same level of treatment support as in-person care links ideas about quality of care to assumptions about patient populations and their needs. Participant 24, also a nurse practitioner, felt that in-person treatment allows providers to build more trust and accountability with patients who may be struggling: I feel like it’s a viable option for people who have some level of stability within their MOUD treatment that don’t necessarily feel like they would benefit from a one-on-one, like, face-to-face check-in…The only question is like for people who are…you’re concerned that they may still be using or have a high risk of overdose—do in-person visits offer something that telehealth doesn’t in terms of being able to build trust and accountability? As discussed above, providers feel they can see and notice things in person they might not over telehealth, and thus are less enthusiastic about telehealth for patients whom they distrust and believe need more supervision. Participant 10, a program coordinator, more explicitly voiced not-uncommon provider concerns over diversion or dishonesty: I guess for patients who it seems kind of less appropriate [for], is the people who we’re seeing adulterated [drug screens], or we don’t feel like we’re getting consistent stories, or who are really still endorsing high levels of use, patients who it seems pretty obvious are struggling…we’d want to see those patients in person. When asked about why providers might not want to use telehealth, participant 10 cited “concerns around toxicology” as “the number one reason.” Providers often brought up urine drug screens (UDS) in discussions of telehealth, either as a concern of their own or as what they perceived to be of concern to others. Even when providers did not see UDS as the most important indicator of someone’s recovery (and participants varied widely in how they understood and used drug screens as a tool), it was generally understood to go along with in-person care in helping ensure providers can closely monitor patients. Many providers expressed a sense of wariness around regulatory standards and compliance, which often encouraged a desire to keep patients within sight: Participant 23, a nurse practitioner, reflected: I think it’s so hard in the MOUD world, because I think people – Suboxone and other formulations, is controlled right now. So I think there’s some fear around that and prescribing it and keeping to standards. And then also urine drug screenings and being positive for other substances, which may or may not indicate how well someone’s doing or how they’re doing in their recovery or their adherence to their medication. But yeah…I think in some cases that might be detrimental to someone if they are motivated to be in recovery and they want to take their medication, but we’re not seeing them in person, or if there’s issues with a urine drug screening, it might be better to bring them in a little closer instead of keeping distance by talking to them on the phone. In this account, this provider links concerns about regulatory issues and toxicology to a sense that it may feel more comfortable for providers to keep patients “closer” by seeing them in person. In some cases, providers were more explicitly worried about diversion and dishonesty from their patients, which they felt made them less appropriate candidates for telehealth. As Participant 4, a medical director, reflected: You always worry that people are just playing you and selling it, and buying things. But I’m never certain. I would say come and give your urine, keep Suboxone in your urine, and make your appointments, and do everything right, and we’ll never have a problem. In addition to helping manage their own fears around regulatory standards, given these assumptions and concerns, many providers saw telehealth as something of a reward to be earned for good behavior, compliance, and the achievement of a required level of stability. Participant 24, a nurse practitioner, noted: I think it’s offered as a reward of, you know, you’re doing really well, you’ve achieved this goal of being able to get like a two-month script. We just want to make sure that you’re continuing to do good. So like here’s telehealth as an option. Participant 7, a mental health counselor, agreed: And then we treated telehealth as sort of like a graduation point. Like if you demonstrate adherence, things are going well, you’re meeting with your case manager, there was like a point in time that was sort of a benchmark where we could start offering maybe telehealth one month, in person check-in, and then telehealth. Once again invoking relational (building trust and rapport), informational (oversight and mistrust), and structural (technological literacy and access) features, some participants see telehealth as best suited to the adherent, employed, trustworthy patients they understand to be sufficiently stable to benefit from this modality of care. 2.2“Telemedicine Helps Our Most Vulnerable People”: Best for Less Stable Patients. “Telemedicine Helps Our Most Vulnerable People”: Best for Less Stable Patients. While for most of the providers we spoke with, it was stable patients who were considered the most appropriate subjects for tele-bupe, others acknowledged the ways that less stable, more vulnerable patients might in fact benefit from it the most. Although some cited technological literacy and access to technology as barriers to telehealth for “unstable” patients, other providers noted how telehealth could overcome barriers to care and make treatment more available to those who would not usually be offered it: Participant 24, a nurse practitioner, noted: I think we lose people…our clinic’s 9:00 to 5:00, and our MOUD times are very specific. So it’s hard for people…our clinic only works for people who are able to have a consistent day off work a week. And I think telehealth has a lot of advantages to help make MOUD more accessible to people that we don’t necessarily offer [it to]. Some providers pointed out that telehealth also helps counteract the stigma patients—especially those who are more marginalized, unstable, or socially precarious—might face in seeking in-person treatment, either from medical providers not specifically trained to work with these populations, or from the general public. Participant 5, a physician and medical director, reflected on how primary care practices that are “not ready” for MOUD patients can fail to offer them non-stigmatizing care: I used to feel very strongly that everybody in primary care should be doing a lot of buprenorphine…but it’s a huge culture shift, and it’s kind of hard for the staff and the office. They’re just not used to the population and the way they approach their needs, and it ends up being more stigmatizing to the patients trying to bring them into a primary care practice that’s not ready for them, so I think telehealth…like have a practice champion and maybe increase the access by some visits being telehealth… I think is a really good model. In explaining his enthusiastic support for telehealth, participant 8, a physician and medical director, offered an extended reflection on one of his patients, noting how in her small, rural community, seeking in-person care can subject people to stigma and unwanted attention and exposure: She lives in a rural conservative community. And she couldn’t get Suboxone treatment. And we would try to get her to come in person. And she said that they looked at her funny when she would try to get on the bus. And this is somebody whose drug use is very visible. If you saw her, you would just be able to identify that she has a drug problem. And here that’s often viewed as a moral failing. So she’s not treated well when she tries to get on the bus. So that’s somebody who I feel like we’ve been able to engage with telemedicine because it overcomes the transportation barrier. He saw telehealth overall as an important option for avoiding stigmatizing environments, offering patients access to non-judgmental, high-quality care that they will actually pursue: [It’s] better for the marginalized, vulnerable people. Because there’s nothing I can do. I can give—if you saw how many presentations I gave to clinical support staff and front desk staff around stigma reduction, I worked pretty hard, but it’s just there. You know what I mean? Like it’s just not gonna be a good experience for them all the time coming into the office. The telemedicine helps our most vulnerable people. That’s for sure. Because it’s what results in a completed appointment. Participant 15, a physician assistant, argued that telehealth is most useful and appropriate for both the most and least stable patients: Like, very stable or very unstable kind of spectrum. I think the two ends of spectrum is where [telehealth] fills a gap. People that are very stable, that don’t need to come in, that it’s okay if they skip a month if they’re out of state, or working, or attending to something else. We have a patient with eight children under the age of ten. So commitments like that…and if we know a patient is stable, or patients are unstable and they cannot come in, sometimes the same type of commitments, or sometimes just because missing appointments or using drugs and not able to come in, so then it fills that gap too. Highly vulnerable or “unstable” patients are here understood to benefit from telebupe’s comparative ease of access, removing potential barriers and encouraging enhanced anonymity, continuity, and comfort. 3“Some Care is Better than No Care”: Telehealth as “Better than Nothing”. “Some Care is Better than No Care”: Telehealth as “Better than Nothing”. While providers may disagree, or feel ambivalent about, the extent to which telehealth compares in quality with in-person treatment, or about which patients are its most appropriate subjects, there was widespread agreement that, as participant 19 put it: “the alternative is that they’re not getting care at all. And I think some care is better than no care.” Given the near-consensus that telehealth can be accessible to patients when other forms of treatment are not, participants often emphasized that even if imperfect, telehealth was still “better than nothing.” Participant 9, a clinical director, offered a fairly typical reflection on how telehealth acts as a flexible option that reaches patients who might otherwise forego treatment altogether: I think it’s a great option. I think that when we can meet with folks in person it can be better, but also if the option is between tele[health] and nothing, I’d rather folks have tele[health]. I work completely remotely, so I may have a bias here. With some of the patients I work with doing therapy, I would rather meet with them in person, but our ability to do tele[health] is what allows us to keep working together. And I also know with some of the people I work with, they would not come into the office. I’d rather be able to call them while they’re at home or wherever else and us be able to do therapy together than them just not have any support because that is what would happen. While in this case they were discussing addiction-focused talk therapy rather than MOUD appointments, participant 9 acknowledged that whatever might be gained in person—“I do think there’s something very special about being in the room with someone,” she insists—would be lost anyway if someone cannot or will not make it in for a session: I know that a lot of folks just aren’t going to make the time or have the time to come in and do that. So, yeah, it’s definitely prioritizing, having some services over none for me. Telehealth is thus seen as a means of removing other barriers to care; as participant 7 put it: The answers are going to come down to, well, if that’s the barrier, if that’s the threshold, like I’m for it. Even if it means it’s not my first preference, or my clinical preference. While most participants who expressed this “better than nothing” mentality were comparing telehealth unfavorably to a more ideal standard of what they understood as high quality, in-person care, others interpreted telehealth’s (worthwhile, if limited) benefits in comparison to the largely inadequate systems of treatment and support that exist in the contemporary United States. Participant 18, a project manager, saw telehealth’s limitations as relatively similar to those present in in-person care. I think there are of a lot of clinics, like, in-person clinics for Suboxone, that are just really not great, and kind of cogs in the machine…I don’t think that care is spectacular in terms of, like, you know, [being] patient-centered, comprehensive, necessarily, but it is addressing medical needs, and getting people medication and adhering to the governmental, like, the legislation, the policies, all of that….So, I mean, comparatively…I think that so much of the care could be improved in terms of providing more comprehensive care and other options of services. But I think those are also things that don’t come in often with in-person clinics…I don’t necessarily see the telehealth version being that different than some of these other clinics that exist already in-person. They noted how in some cases, even “in-person” care is de-facto telehealth, although it may not be described as such by the clinic. I know one [clinic] even has…the provider isn’t even there in person. They just have the patient set up with, like, in front of a little iPad. And, in all honesty, I actually don’t know if they’re – at least I think in, like, the zeitgeist, they’re not considered virtual…they’re still considered in person. While telehealth may be limited in what it can offer, these limitations, for participant 18, were not so different from those faced by in-person clinics, who also often become “cogs in the machine” dispensing medication rather than spaces of more comprehensive social, medical, and psychological services. Taking a harm reduction approach and attentive to the broader social and political context of drug use and treatment, participant 6, a care manager, saw tele-bupe as one harm-reduction measure in the face of a system that fails to offer meaningful and sufficient support for people with OUD: The crux of it is that I don’t really think Suboxone access should be gatekept at all. I don’t think someone is going to receive recovery care, if they’re not coming in in-person, really. I don’t think they’re going to be receiving the quality level of care that they would need to enter effective recovery…Wraparound care is not accessible for people who are in active street drug addiction. Good recovery care would be giving people houses, you know? It would be safe injection sites. It would be all these other things. Suboxone is not going to solve a person’s problems alone…However, it has a lot of potential as a harm-reductive measure. So while no, I don’t think it’s best practice, so to speak, to do telehealth for people with – to get them buprenorphine, but I don’t care. You know what I mean? Give them the fucking stuff. Faced with the real-world challenges and limitations of existing care for patients with OUD, providers agreed that telehealth, despite its drawbacks and imperfections, was a useful way of getting to treatment to people who may otherwise not have otherwise received it, and one small step in improving a largely inadequate landscape of care. Discussion Providers in this study had mixed opinions about tele-bupe; almost all recognized its benefits in increasing access to treatment and believed that it should have at least some place in the landscape of OUD care. Some thought that it is as good as, if not better than, in-person care; others expressed uncertainty over both the quality of relationships possible in remote care, and the kinds of patients for whom such treatment is appropriate. Many providers are themselves ambivalent, and in interviews, moved back and forth between enthusiasm and hesitancy. Almost all providers we spoke with agreed that, at minimum, MOUD care via telehealth was better than no care at all. While most providers in our sample had some experience with telehealth for MOUD, either during the height of the Covid-19 pandemic or in the wake of its loosened restrictions and expanded use, it remains a relatively new modality for most and its uptake, staying power, and reach will depend, at least in part, on how providers feel about it. The points of disagreement we identify in this article help map the terrain on which these debates unfold and capture areas of reservation and resistance that characterize provider concerns about telehealth. They also expose fault lines where provider assumptions and beliefs may be in tension with the material realities of on-the-ground care today, and with evidence-based research on patient preferences and treatment outcomes for OUD care. Telehealth vs. What? Idealizations of In-person Care One primary point of concern for providers is that telehealth is inherently worse than in-person care for clinical relationships and the establishment of rapport. Such concerns have been well-documented in the literature although existing research, like our own, suggests mixed opinions on this issue [9, 20]. Some providers maintain that telehealth is equivalent or superior to in-person treatment, emphasizing that it makes little difference to the quality of rapport that can be achieved, and noting its improved accessibility and how it enables ongoing caregiving relationships and maintained adherence to treatment. For other providers in our study, the quality of caregiving relationships possible over remote care cannot match that of face-to-face contact. In noting this discrepancy, they describe the in-person clinical dynamic as one of safety, intimacy, and transparency, and the clinical setting as defined by comfort, proximity, privacy, and trust. And yet, this rosy vision of the clinical context does not necessarily resemble actually-existing care for many patients receiving MOUD treatment, nor fully capture how either providers or patients may feel about in-person treatment [54, 55]. Recall provider 18 above, describing in-person clinics as “cogs in the machine” providing care that is not “spectacular” at being “patient-centered” or “comprehensive.” For some patients (and perhaps especially for LGBTQ patients, racially minoritized patients, or other groups often marginalized in healthcare settings), telehealth may increase comfort and safety, making retention more likely and enabling patients to seek care when they may otherwise have avoided it [19, 56]. Telehealth, as has been shown in the case of abortion care, can be especially helpful for medical care that is often stigmatized, mitigating against shame and allowing patients to avoid clinical contexts where such stigma is often enacted [56–58]. Patients may have different understandings of their own comfort than what providers might assume, and clinical environments, which may be comfortable and familiar for providers, and in which they hold the most power and control, may in fact be highly uncomfortable spaces for patients. Indeed, in many cases, patients have been shown to express a preference for tele-bupe, which they see as not only more convenient but also as enabling greater feelings of safety, comfort, and trust with medical providers and allowing them to avoid the potentially stressful, sometimes-oppressive dynamics of the clinical context [19, 20]. This aligns with how some providers saw the benefits of telehealth, which enable relationships to be built and maintained over time in a safe, comfortable, and accessible context, on patients’ own terms. While the desire our participants expressed to foster close, trusting relationships in comfortable, safe clinical spaces is a noble goal, the landscape of care in which many patients seek treatment most often fails to reflect this ideal. As Participant 18 pointed out above, many problems and challenges with tele-bupe also plague in-person care. Not only do most patients who might benefit from MOUD not receive it [59, 60], even when patients are able to access care, it is often rushed, stigmatizing, predatory, or insufficiently inclusive or patient-centered [1, 47, 61–63]. Many patients receive disrespectful, judgmental, or stigmatizing treatment when seeking OUD care [39, 43, 64], and clinical spaces, especially in neighborhoods where drug use is common, can cause distress rather than signifying safety [19, 65]. When participants in our study compare telehealth unfavorably to in-person care, they at times invoke an idealized vision of in-person care that, while reflective of their understandable hopes and aspirations for high-quality in-person treatment for their patients, would seem to be the exception rather than the norm for many patients seeking and receiving care today. Telehealth for Whom? Ideal and Less-than-ideal Patients If provider concerns over relationships and quality of care in telehealth rely, in part, on a comparison to a best-case version of in-person treatment, they also rely on particular ideas about patient behavior, capacity, and trustworthiness, and emerge in a context of widespread anxiety about regulatory compliance amid government policies and rhetoric that seek to crack down on harm reduction and addiction treatment services [66, 67]. Some provider concerns and hesitations about telehealth are related to common assumptions about patients seeking MOUD care, relying on a kind of intuitive (yet sometimes unexamined) sense of what is best for patients and who deserves (and is capable of benefiting from) what forms of care. While some of the providers interviewed emphasized tele-bupe’s accessibility and ease of access as a core benefit of the modality, others were committed to the idea that recovery takes work and should require effort to be successful; for these providers, the fact that telehealth removes barriers and facilitates access to care was seen as a problematic feature, preventing patients from engaging in the “real” work of managing their OUD and “earning” their recovery. Given the demonstrated efficacy of MOUD as compared with other modes of non-medical (and often more moralistic) treatment models [68, 69], and that accessing evidence-based care consistently saves lives, it is noteworthy that some providers make the argument that making care more difficult to obtain can be in the service of patients. Provider concerns about telehealth for MOUD can involve a tacit mistrust of patients and a concomitant desire to more closely observe them. Some providers express concerns about urine drug screens (despite the fact that such screens can be done virtually over telehealth [70], and that falsification is no higher over telehealth than in person [71]), and state that they want to see patients in person so they can more accurately assess their situations, including detecting whether or not they are lying about drug use, diversion, or other behaviors. This attitude reveals the misgivings and anxiety with which some providers may view their MOUD patients, even as they seek to provide them with the best, most appropriate care. In an ever-shifting regulatory environment and a context of ongoing hostility towards low-barrier care and harm reduction services [49, 72], these reservations reflect not only common modes of internalized stigma against patients with OUD, but also understandable provider concerns and anxieties about the importance of maintaining compliance and protecting their own reputations and practices. For almost all providers we interviewed, “stability” was the most important consideration in weighing which patients are appropriate candidates for telehealth MOUD. Bundling together factors like socioeconomic status, time in treatment, employment, medication adherence, technological competency, and an implicit sense of trustworthiness, stability functions as something of a flexible, floating signifier that enables providers to make determinations about who should have access to what forms of care [22]. As the differences in opinion across providers we interviewed highlight, the same factors that make a patient unstable—poverty, homelessness, social precarity, trouble maintaining adherence—make all forms of treatment (not just tele-bupe) more difficult to access, and make these patients the least likely to receive and sustain care at all. Some of the providers we spoke with believed that it is the most “unstable” (or, put otherwise, vulnerable) patients who are most likely to not receive care, and to therefore benefit most from a more flexible, lower-barrier system. Indeed, these debates mirror broader conversations over harm-reduction and low-barrier care in treating substance use disorders [35, 73, 74] as well as political debates and crackdowns over low-barrier services, both nationally and in Philadelphia [75–77]. Opinions about the role of stability are thus critical to provider assessments of tele-bupe and who it may benefit the most. Having been more exposed to tele-bupe since the onset of the pandemic, providers, our data shows, are still grappling with its benefits and challenges. While almost all the providers we interviewed view the addition of telehealth to available treatment options favorably, emphasizing superior accessibility, its ability to support retention in care and foster longer-term care relationships, and its success at enabling providers to create and maintain rapport with patients, major points of ambivalence are tied to assumptions about the actual state of existing options for care and about the patients it aims to treat. These assumptions bear investigation as telehealth may become more durably integrated into the treatment landscape, and provider opinions and preferences will shape the extent of telehealth’s uptake and the patients to whom it is offered. In important ways, concerns about and debates over telehealth echo and restage familiar debates over lower-barrier care in substance use disorder treatment more broadly. Limitations Because our sampling method relied on purposive and snowball sampling, was limited to the Southeastern Pennsylvania area, and our sample skewed white and female, participants may not be representative of a more general population of MOUD clinicians. Participants also varied widely in their professional roles and, while all had direct experience with patient care, their levels of experience with tele-bupe varied. However, our goal in this paper is not to provide a comprehensive account of all MOUD providers’ views of telehealth but, rather, to offer a close-up account of how certain providers adjudicate telehealth’s promises and pitfalls, and to explore the assumptions, forms of reasoning, and concerns that constitute ongoing sites of hesitancy that may shape the provision (or denial) of telehealth to OUD patients. Because of the stricter regulations surrounding methadone provision in the US, we did not include providers working in environments where only methadone is provided. We also did not include employees of telehealth-only OUD treatment companies; while research with such providers would offer valuable perspectives on tele-bupe, our focus here was on where, how, and why telehealth is being integrated (or not) into traditional sites of OUD care. The themes addressed in this paper emerged inductively from our interviews with providers. More deliberate, focused work specifically exploring these areas of hesitation with a broader range of OUD providers would offer greater insight into both the nature of provider concerns and the prevalence of these beliefs within a larger population of clinicians. Further research with patients is a critical complement to this work with providers, and would shed light on their own experiences with and opinions about tele-bupe and its benefits and challenges. Conclusion Our qualitative study of 25 providers in Southeastern Pennsylvania suggests that even as telehealth MOUD has become much more widely used and accepted since the onset of the Covid-19 pandemic, many providers remain ambivalent—if overall positive—about the quality of care it provides and the patients for whom it is indicated. Exploring these points of ambivalence and disagreement, we show how particular assumptions, anxieties, and imaginaries about both in-person care and patient needs structure hesitation about telehealth for MOUD; telehealth is compared unfavorably to an aspirational vision of an idealized in-person care that does not align with what care actually looks like for most patients, and its use is questioned for patients deemed insufficiently “stable” to succeed without the oversight providers associate with in-person treatment. As the field continues to strategize about how to improve access to and retention in evidence-based OUD treatment, these findings help shed light on why some clinics and providers may support or avoid tele-bupe in their work, and for which patients they might be more likely to offer this treatment option. Understanding these perceptions and reactions may inform the design of better training for clinicians and interventions to increase comfort, address hesitation, and foster a supportive climate for expanded uptake of flexible, accommodating treatment options. Acknowledgements We would like to thank the providers in this study who generously shared their time and perspectives. Author contributions SA conceived and supervised the study; SA and EF collected the data, NZ, SA and EF completed the analyses, NZ and SA led the writing; JC and DM assisted with the study and writing. Funding This study was funded by National Institute On Drug Abuse of the National Institutes of Health under Award Number K23DA057528. Dr. Zucker’s efforts were also supported by the Penn Injury Science Center. Data availability The data generated and analyzed during the current study are not publicly available to protect the identities of study participants. Declarations Competing interests The authors declare no competing interests. Ethics Approval All study protocols were reviewed and approved by the University of Pennsylvania Institutional Review Board (IRB), Reference Number 851652. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data generated and analyzed during the current study are not publicly available to protect the identities of study participants.